Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	7.34	10.02	8.4	0.03
Cash & Short-Term Investments	7.34	10.02	8.4	0.03
Cash Growth	11.72%	19.23%	25685.61%	-
Other Receivables	0.02	0.04	0.04	-
Receivables	0.02	0.04	0.04	-
Prepaid Expenses	0.58	0.04	0.05	0.02
Other Current Assets	0.01	0.01	-	0.67
Total Current Assets	7.94	10.11	8.49	0.73
Property, Plant & Equipment	0	0.01	0.02	0.04
Other Long-Term Assets	0	0	0	0.01
Total Assets	7.95	10.12	8.52	0.78
Accounts Payable	1.28	1.5	0.17	0.4
Accrued Expenses	0.56	1.18	0.64	0.86
Short-Term Debt	-	-	-	0.04
Current Portion of Leases	-	-	0.02	0.02
Total Current Liabilities	1.84	2.68	0.83	1.33
Long-Term Debt	-	-	-	0.55
Long-Term Leases	-	-	-	0.02
Other Long-Term Liabilities	-	-	-	4.42
Total Liabilities	1.84	2.68	0.83	6.33
Common Stock	0	0	0	0.01
Additional Paid-In Capital	35.68	33.16	22.76	1.15
Retained Earnings	-29.57	-25.72	-15.07	-6.71
Shareholders' Equity	6.11	7.44	7.69	-5.55
Total Liabilities & Equity	7.95	10.12	8.52	0.78
Total Debt	-	-	0.02	0.64
Net Cash (Debt)	7.34	10.02	8.38	-0.61
Net Cash Growth	11.98%	19.53%	-	-
Net Cash Per Share	5.19	8.21	9.32	-1.16
Filing Date Shares Outstanding	1.97	1.88	1.07	0.78
Total Common Shares Outstanding	1.91	1.78	0.87	0.55
Working Capital	6.1	7.43	7.67	-0.61
Book Value Per Share	3.20	4.17	8.86	-10.16
Tangible Book Value	6.11	7.44	7.69	-5.55
Tangible Book Value Per Share	3.20	4.17	8.86	-10.16

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q